Therapeutic Strategy for Recurrent Ulcerative Colitis

Anak Agung Ngurah Satya Pranata(1), I Made Suma Wirawan(2), Anak Agung Istri Sri Kumala Dewi(3), Novitasari .(4),


(1) Medical Intern, Department of Internal Medicine, Wangaya Regional General Hospital, Bali
(2) Department of Internal Medicine, Wangaya Teaching General Hospital/ Medical Faculty of Universitas Mahasaraswati Denpasar, Bali
(3) Department of Internal Medicine, Wangaya Teaching General Hospital/ Medical Faculty of Universitas Mahasaraswati Denpasar, Bali
(4) Department of Pathological Anatomy, Wangaya Regional General Hospital/Medical Faculty of Universitas Mahasaraswati Denpasar, Bali
Corresponding Author

Abstract


Ulcerative Colitis (UC) is a chronic idiopathic inflammation that appears from the rectum and can extend to colon causing diffuse friability and superficiality. In this case report, Woman, 44 years old, admitted to hospital because of bloody diarrhea, frequency of 4-6 times daily with mucous, malaise, and history of weight loss. Patient already had oral sulfasalazine and oral corticosteroid to maintain her condition, but she stopped the medication at will. On physical examination, showed anemic conjunctiva and increasing in bowel sound, fecal examination showed brown to red, porridge-like consistency, blood, mucous, and positive Benzidine test. Colonoscopy examination revealed, normal anus; in the sigmoid rectum, colon descendent found small swellings, an ulcer, and few bloody. On histopathology, epithelial surface with mucin depletiondistortion of crypt architecture, dilatation and elongation of crypt, as well as shortening of the crypt that does not reach muscular mucous and lamina propria contains solid aggregate inflammation cells, dominated by plasma cells. The patient was given  combination of 5-aminosalicylates and glucocorticoids. On re-evaluation in week 8 of therapy, frequency of defecation becomes 1-2 times daily with no blood occurring and improvement on colonoscopy, rectal mucous, colon sigmoid improved, no bleeding and clean mucous.  5-aminosalicylates is the first treatment in UC,  it also helps to achieve remission and prevent carcinoma development. UC is a disease that also causes extra-intestinal manifestation, so the treatment should be done holistically. Compliance and regular monitoring will help to improve the quality of life.

 


Keywords


Gastrointestinal, irritable bowel syndrome, ulcerative colitis

References


OrdaÌis I, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ. Ulcerative colitis. Lancet [Internet]. 2012;380(9853) [cited 2024 Mar 30] :1606–19. Available from: http://dx.doi.org/10.1016/S0140-6736(12)60150-0

Gajendran M, Loganathan P, Jimenez G, Catinella AP, Ng N, Umapathy C, et al. A comprehensive review and update on ulcerative colitis, Disease-a-Month. 2019;65(12).

Segal JP, Jean-Frédéric LeBlanc A, Hart AL. Ulcerative colitis: An update. Clin Med J R Coll Physicians London. 2021;21(2):135–9.

Nigg JT.Perubahan Genetik. NIH Public Access. Bone. 2008;23(1):1–7.

Feuerstein JD, Moss AC, Farraye FA. Ulcerative Colitis. Mayo Clin Proc [Internet]. 2019 [cited 2024 Mar 30];94(7):1357–73. Available from: https://doi.org/10.1016/j.mayocp.2019.01.018.

Lee JS, Kim ES, Moon W. Chronological review of endoscopic indices in inflammatory bowel disease. Clin Endosc. 2019;52(2):129–36.

D’Amico F, Magro F, Caron B, Dignass A, Jairath V, Hart A, et al. iSTART-II: An Update on the i Support Therapy–Access to Rapid Treatment (iSTART) Approach for Patient-Centered Therapy in Mild-to-Moderate Ulcerative Colitis. J Clin Med. 2023;12(3):522–8.

Van Assche G, Dignass A, Panes J, Beaugerie L, Karagiannis J, Allez M, et al. The second European evidence-based consensus on the diagnosis and management of Crohn’s disease: Definitions and diagnosis. J Crohn’s Colitis [Internet]. 2010[cited 2024 Mar 30];4(1):7–27. Available from: http://dx.doi.org/10.1016/j.crohns.2009.12.003

Gizard E, Ford AC, Bronowicki JP, Peyrin-Biroulet L. Systematic review: The epidemiology of the hepatobiliary manifestations in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2014;40(1):3–15.

Halling ML, Kjeldsen J, Knudsen T, Nielsen J, Hansen LK. Patients with inflammatory bowel disease have increased risk of autoimmune and inflammatory diseases. World J Gastroenterol. 2017;23(33):6137–46.

Annese V, Daperno M, Rutter MD, Amiot A, Bossuyt P, East J, et al. European evidence based consensus for endoscopy in inflammatory bowel disease. J Crohn’s Colitis [Internet]. 2013 [cited 2024 Mar 30];7(12):982–1018. Available from: http://dx.doi.org/10.1016/j.crohns.2013.09.016.

Magro F, Langner C, Driessen A, Ensari A, Geboes K, Mantzaris GJ, et al. European consensus on the histopathology of inflammatory bowel disease. J Crohn’s Colitis [Internet]. 2013 [cited 2024 Mar 30];7(10):827–51. Available from: http://dx.doi.org/10.1016/j.crohns.2013.06.001.

Shah SC, Colombel JF, Sands BE, Narula N. Mucosal Healing Is Associated With Improved Long-term Outcomes of Patients With Ulcerative Colitis: A Systematic Re

iew and Meta-analysis [Internet]. Vol. 14, Clinical Gastroenterology and Hepatology. Elsevier Ltd; 2016 [cited 2024 Mar 30]. 1245-1255.e8 p. Available from: http://dx.doi.org/10.1016/j.cgh.2016.01.015

Borman ZA, Côté-Daigneault J, Colombel JF. The risk for opportunistic infections in inflammatory bowel disease with biologics: an update. Expert Rev Gastroenterol Hepatol [Internet]. 2018 [cited 2024 Mar 30] ;12(11):1101–8. Available from: https://doi.org/10.1080/17474124.2018.1530983.

Damme V. ICMJE Form for Disclosure of Potential Conflicts of Interest ICMJE Form for Disclosure of Potential Conflicts of Interest. 2009;1–4. Available from: http://www.icmje.org/

Sandborn WJ, Feagan BG, Marano C, Zhang H, Strauss R, Johanns J, et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology [Internet]. 2014 [cited 2024 Mar 30];146(1):96-109.e1. Available from: http://dx.doi.org/10.1053/j.gastro.2013.06.010.

Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis. Lancet. 2017;389(10080):1756–70.


Full Text: PDF

Article Metrics

Abstract View : 68 times
PDF Download : 11 times

DOI: 10.24871/253202484-89

Refbacks

  • There are currently no refbacks.